FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4229947110> ?p ?o ?g. }

• W4229947110 endingPage "360" @default.
• W4229947110 startingPage "357" @default.
• W4229947110 abstract "Estradiol, estrone, and estrone sulfate are the primary circulating estrogens in women; the relative amounts depend on the menopausal status of the women. Administration of oral estradiol or conjugated equine estrogens (CEE) results in a high ratio of estrone to estradiol, whereas use of nonoral routes (dermal, vaginal, or parenteral) results in approximately equal plasma concentrations of estradiol and estrone. Although estradiol and estrone are predominately eliminated by metabolism, and little is excreted unchanged in the urine, evidence indicates that chronic kidney disease (CKD) alters the pharmacokinetics of estradiol. Free and total estradiol plasma concentrations are higher in women with end-stage renal disease (ESRD) after an oral estradiol dose, but no change occurs in estrone concentrations. Neither estradiol nor estrone is removed in the dialysate. These studies suggest that women with CKD should receive a least a 50% reduction in oral estradiol doses. No information is available on the pharmacokinetics of any of the progestins in CKD. In the future, knowledge of the concentration effect relationship for the treatment of symptoms of menopause, as well as prevention of osteoporosis, will benefit all postmenopausal women who choose to use hormone replacement therapy. Estradiol, estrone, and estrone sulfate are the primary circulating estrogens in women; the relative amounts depend on the menopausal status of the women. Administration of oral estradiol or conjugated equine estrogens (CEE) results in a high ratio of estrone to estradiol, whereas use of nonoral routes (dermal, vaginal, or parenteral) results in approximately equal plasma concentrations of estradiol and estrone. Although estradiol and estrone are predominately eliminated by metabolism, and little is excreted unchanged in the urine, evidence indicates that chronic kidney disease (CKD) alters the pharmacokinetics of estradiol. Free and total estradiol plasma concentrations are higher in women with end-stage renal disease (ESRD) after an oral estradiol dose, but no change occurs in estrone concentrations. Neither estradiol nor estrone is removed in the dialysate. These studies suggest that women with CKD should receive a least a 50% reduction in oral estradiol doses. No information is available on the pharmacokinetics of any of the progestins in CKD. In the future, knowledge of the concentration effect relationship for the treatment of symptoms of menopause, as well as prevention of osteoporosis, will benefit all postmenopausal women who choose to use hormone replacement therapy." @default.
• W4229947110 created "2022-05-11" @default.
• W4229947110 creator A5027464695 @default.
• W4229947110 creator A5085266072 @default.
• W4229947110 date "2004-10-01" @default.
• W4229947110 modified "2023-09-25" @default.
• W4229947110 title "Pharmacokinetics of estrogen and progesterone in chronic kidney disease" @default.
• W4229947110 doi "https://doi.org/10.1016/s1548-5595(04)00114-4" @default.
• W4229947110 hasPublicationYear "2004" @default.
• W4229947110 type Work @default.
• W4229947110 citedByCount "4" @default.
• W4229947110 countsByYear W42299471102013 @default.
• W4229947110 countsByYear W42299471102021 @default.
• W4229947110 crossrefType "journal-article" @default.
• W4229947110 hasAuthorship W4229947110A5027464695 @default.
• W4229947110 hasAuthorship W4229947110A5085266072 @default.
• W4229947110 hasConcept C112705442 @default.
• W4229947110 hasConcept C126322002 @default.
• W4229947110 hasConcept C134018914 @default.
• W4229947110 hasConcept C2777164284 @default.
• W4229947110 hasConcept C2778562196 @default.
• W4229947110 hasConcept C2778656385 @default.
• W4229947110 hasConcept C2779149875 @default.
• W4229947110 hasConcept C2780026642 @default.
• W4229947110 hasConcept C71315377 @default.
• W4229947110 hasConcept C71924100 @default.
• W4229947110 hasConceptScore W4229947110C112705442 @default.
• W4229947110 hasConceptScore W4229947110C126322002 @default.
• W4229947110 hasConceptScore W4229947110C134018914 @default.
• W4229947110 hasConceptScore W4229947110C2777164284 @default.
• W4229947110 hasConceptScore W4229947110C2778562196 @default.
• W4229947110 hasConceptScore W4229947110C2778656385 @default.
• W4229947110 hasConceptScore W4229947110C2779149875 @default.
• W4229947110 hasConceptScore W4229947110C2780026642 @default.
• W4229947110 hasConceptScore W4229947110C71315377 @default.
• W4229947110 hasConceptScore W4229947110C71924100 @default.
• W4229947110 hasIssue "4" @default.
• W4229947110 hasLocation W42299471101 @default.
• W4229947110 hasOpenAccess W4229947110 @default.
• W4229947110 hasPrimaryLocation W42299471101 @default.
• W4229947110 hasRelatedWork W1489680136 @default.
• W4229947110 hasRelatedWork W1621741447 @default.
• W4229947110 hasRelatedWork W1985471892 @default.
• W4229947110 hasRelatedWork W2003738655 @default.
• W4229947110 hasRelatedWork W2009886020 @default.
• W4229947110 hasRelatedWork W2060300693 @default.
• W4229947110 hasRelatedWork W2061506259 @default.
• W4229947110 hasRelatedWork W2120682794 @default.
• W4229947110 hasRelatedWork W2130662388 @default.
• W4229947110 hasRelatedWork W4293589886 @default.
• W4229947110 hasVolume "11" @default.
• W4229947110 isParatext "false" @default.
• W4229947110 isRetracted "false" @default.
• W4229947110 workType "article" @default.